Compare CNK & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CNK | TNGX |
|---|---|---|
| Founded | 1984 | 2014 |
| Country | United States | United States |
| Employees | 18300 | N/A |
| Industry | Movies/Entertainment | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.1B | 4.1B |
| IPO Year | 2007 | 2020 |
| Metric | CNK | TNGX |
|---|---|---|
| Price | $37.74 | $25.02 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 10 |
| Target Price | ★ $33.70 | $21.78 |
| AVG Volume (30 Days) | 1.8M | ★ 2.5M |
| Earning Date | 05-01-2026 | 05-08-2026 |
| Dividend Yield | ★ 1.24% | N/A |
| EPS Growth | N/A | ★ 26.89 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $3,115,000,000.00 | $62,384,000.00 |
| Revenue This Year | $11.01 | N/A |
| Revenue Next Year | $3.70 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 2.15 | ★ 48.29 |
| 52 Week Low | $21.60 | $6.69 |
| 52 Week High | $38.98 | $34.39 |
| Indicator | CNK | TNGX |
|---|---|---|
| Relative Strength Index (RSI) | 65.08 | 54.10 |
| Support Level | $36.28 | $19.74 |
| Resistance Level | $38.91 | $26.09 |
| Average True Range (ATR) | 1.14 | 1.60 |
| MACD | 0.27 | 0.34 |
| Stochastic Oscillator | 99.32 | 80.99 |
Cinemark Holdings Inc is a geographically diverse operator in the motion picture exhibition industry in the United States. The company generates revenue from filmed entertainment box office receipts and concession sales, with additional revenue from screen advertising, screen rentals, and other revenue streams, such as transactional fees, vendor marketing promotions, studio trailer placements, meeting rentals, and electronic video games located in some of the theatres. Cinemark manages its business under two reportable segments: U.S. markets and international markets. The majority of its revenue is generated from the U.S. markets segment.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.